Living in an increasingly sanitized world, frequently adopting an inadequate diet and consuming excessive amounts of medication, we must admit our responsibility towards the imbalance of our intestinal microbiota.
These disorders, or dysbioses, can unfortunately cause various abdominal inflammatory conditions, such as Crohn’s disease and ulcerative colitis, irritable bowel syndrome, metabolic diseases and autoimmune disorders. To remedy this situation, certain bacterial strains contained in probiotics, “living microorganisms that, when administered in sufficient quantities, confer a beneficial effect on the health of the host,” can help prevent inflammation. While not all probiotics available on the market offer these advantages, new advances suggest a real potential towards certain classes of probiotics to reduce nosocomial diseases.
A Brand-new Study
Recently, recognizing a significant problem in hospital settings due to numerous cases of Clostridium difficile (CDI) infections, researchers have studied the benefits of adding a probiotic component of antibiotic treatment prescribed to patients in order to prevent this infection. The probiotic described in the manuscript, Bio-K+ (composed of L. acidophilus CL1285, L. casei LBC80R and L. rhamnosus CLR2), contains a bacterial composition that shown to be effective in the primary prevention of DCI. Indeed, when used in hospitals, it shows reductions in STD rates, even those sustained over the years. For more information…
This Year at BÉNÉFIQ 2018
We have the honour to welcome Mrs. Solange Hanoud, from Lallemand Health Solutions, to present the position of the International Probiotics Association (IPA) on the regulatory guidelines for probiotics. Moreover, it is with pleasure that the 2018 “Grande Québécoise” Bio-K+ will co-chair the session on microbiota and metabolic health on October 3. An event not to be missed!